Current stock page

Financial Data

ABCL Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ABCLAbCellera Biologics Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$11.49−$0.13 (−1.12%)

Latest quote

  • Momentum
    89
  • Value
    47
  • Quality
    61
  • Risk resilience
    34
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$10.64M$4.05M$8.32M$44.85M$8.96M$17.08M$4.24M$5.05M
Gross Profit$10.64M$4.05M-$340K$36.93M$8.96M$17.08M$4.24M$5.05M
Operating Income-$53.32M-$62.78M-$57.52M-$28.58M-$76.28M-$49.59M-$62.66M-$72.76M
Net Income-$40.76M-$55.43M-$43.17M-$8.95M-$57.12M-$34.73M-$45.62M-$34.21M
EPS-$0.13-$0.18-$0.14-$0.03-$0.19-$0.12-$0.15-$0.12
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$26.91M-$33.86M-$33.52M-$34.74M-$52.59M-$32.4M-$11.55M-$8M
Capital Expenditure-$1.61M-$2.13M-$3.83M-$9.84M-$8.93M-$13.37M-$10.64M-$15.63M
Free Cash Flow$25.3M-$36M-$37.35M-$44.59M-$61.52M-$45.77M-$22.19M-$23.63M
Net Cash Provided By Operating Activities$26.91M-$33.86M-$33.52M-$34.74M-$52.59M-$32.4M-$11.55M-$8M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.5B$1.31B$1.31B$1.36B$1.36B$1.4B$1.34B$1.36B
Total Debt$133.82M$135.62M$140.18M$143.22M$142.22M$142.08M$67.85M$65.36M
Cash And Cash Equivalents$163.8M$120.07M$77.06M$128.51M$83.16M$92.44M$159.27M$156.33M
Total Liabilities$437.36M$411.56M$369.03M$390.05M$391.95M$394.99M$321.23M$304.47M
Total Stockholders Equity$1.06B$896.02M$938.08M$966.9M$964.04M$1.01B$1.02B$1.06B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.742.021.70.991.41.260.580.81
P/S ratio53.85———————
Debt To Equity0.130.150.150.150.150.140.070.06
Free Cash Flow Yield-2.33%-9.92%-11.89%-18.10%-11.31%-11.00%-23.84%-21.66%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.742.021.70.991.41.260.580.81
P/S ratio53.85———————
Return On Equity-13.96%-18.38%-15.35%-15.14%-17.81%-16.45%-16.41%-15.42%
Debt To Equity0.130.150.150.150.150.140.070.06

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-23.94x
Pb3.44x
Revenue Growth Yoy18.81%
EPS Growth Yoy31.58%
Gross Margin75.57%
Operating Margin-297.97%
ROE-15.35%
ROIC-12.23%
Debt To Equity0.13
FCF Yield-2.47%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$11.49
Volume2.68M
RSI (14)45.24
MACD-0.14
MACD signal-0.07
MACD histogram-0.07
ADX (14)11.89
SMA (50)$12.34
SMA (200)$7.24
ATR (14)$0.94
Historical volatility (annualized)88.85%
Volume (20-day average)3.21M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score34/100
Beta2.42
Annual volatility85.28%
Max Drawdown-40.09%
Sharpe Ratio1.73
VaR (95%, 1-day)-7.07%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ABCL Financial Data FAQ

What is AbCellera Biologics Inc.'s revenue?

AbCellera Biologics Inc.'s revenue is one of the core financial data points for ABCL. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is AbCellera Biologics Inc.'s revenue growing?

Revenue growth shows whether AbCellera Biologics Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ABCL's EPS?

ABCL's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is AbCellera Biologics Inc.'s net income?

AbCellera Biologics Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does AbCellera Biologics Inc. generate?

Free cash flow shows how much cash AbCellera Biologics Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does AbCellera Biologics Inc. have?

Cash and debt help frame ABCL's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.